CORTICOSTEROID REDUCTION IN ASTHMA AND THE BRAIN (CRAB) PILOT PROJECT

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 轻度至中度持续性哮喘患者将接受开放标签序贯减少吸入性皮质类固醇剂量，从220 mcg丙酸氟替卡松每日两次至无吸入性类固醇，目的是降低其哮喘控制水平。 在这项为期10周的研究中，将获得一系列神经影像学研究（fMRI），并在哮喘控制措施（包括症状、生理反应和气道炎症措施）的背景下检查脑反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Mild to moderate persistent asthmatics will undergo an open-label sequential reduction of inhaled corticosteroid dosing, from 220 mcg twice daily of fluticasone propionate to no inhaled steroids, with the goal of reducing their level of asthma control. Serial neuroimaging studies (fMRI) will be obtained over this 10-week study and brain responses will be examined in the context of measures of asthma control (including measures of symptoms, physiologic responses, and airway inflammation).